Claims for Patent: 9,931,380
✉ Email this page to a colleague
Summary for Patent: 9,931,380
Title: | Medicament for treating olfaction disorder |
Abstract: | The object of the present invention is to provide an olfactory disturbance therapeutic agent that is effective in repairing or regenerating olfactory epithelium that suffered damages such as scratches and can be administered for a long time. The object of the present invention is achieved by an olfactory disturbance therapeutic agent including at least one active ingredient that is selected from among a group consisting of insulin, insulin analogs, and insulin secretagogues. Preferably, the olfactory disturbance therapeutic agent is used for people with olfactory disturbance who have, or are at risk of having, impaired insulin secretion or insulin resistance, or for people who could suffer an iatrogenic increase in blood sugar level or a disturbance in a balance of adrenocortical hormone stemming from a long-term use of steroid as olfactory disturbance treatment. |
Inventor(s): | Kuboki; Akihito (Tokyo, JP), Kikuta; Shu (Tokyo, JP) |
Assignee: | |
Application Number: | 15/046,858 |
Patent Claims: | 1. A method of treating an olfactory disturbance using a therapeutic agent comprising: administrating the agent to a patient in need thereof, comprising at least one active
ingredient that is selected from the group consisting of insulin, insulin alpart, insulin lispro, insulin glulisine, insulin degludec, insulin glargine, insulin detemir, and their pharmaceutically acceptable salts, wherein the agent is administrated at
least in the days 7 to 14 after the onset of olfactory epithelium disturbance.
2. The method of treating an olfactory disturbance according to claim 1, wherein the agent is used for people with olfactory disturbance who have impaired insulin secretion or insulin resistance. |
Details for Patent 9,931,380
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 06/14/1996 | ⤷ Try a Trial | 2035-02-19 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 08/06/1998 | ⤷ Try a Trial | 2035-02-19 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 09/06/2007 | ⤷ Try a Trial | 2035-02-19 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 06/06/2017 | ⤷ Try a Trial | 2035-02-19 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 11/15/2019 | ⤷ Try a Trial | 2035-02-19 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.